• Sanwire Corp. is using technology to consolidate services in fragmented markets. The company is currently focused on advanced entertainment technologies.
• The acquisition of Intercept Music Inc. gave Sanwire solid footing in the music and entertainment industry, offering a unique suite of artist-focused services specifically created for recording artists.
• During the second quarter of 2020, Sanwire’s revenues increased by approximately 300% following its acquisition of Intercept Music Inc. Further growth is expected throughout the balance of 2020.
• On June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart.

Sanwire Corp. (OTC: SNWR) is a diversified company currently focused on technologies for the music industry. The company specializes in locating unique opportunities in fragmented markets and implementing its aggregated technologies to consolidate distinct services into unified platforms of delivery. Sanwire is currently focusing these efforts on advanced entertainment technologies.

Founded in 1997 and based out of Las Vegas, Nevada, Sanwire has operated and sold several subsidiaries as it has worked in various industry segments, including Sanwire Software Inc., Bullmoose Mines Ltd. and Squeeze Report Inc. Currently, there are two new holdings that were added to the company’s portfolio through two recent acquisitions, including Intercept Music Inc. in March 2020 and the Art is War Record Label in June 2020.

Intercept Music Inc. – Artist-Focused Services

Intercept Music Inc. is an entertainment technology company offering a unique suite of artist-focused services that are specifically designed to meet the needs of recording artists. Intercept’s proprietary online platform is dedicated to helping millions of global independent artists effectively promote their music and distribute it worldwide to hundreds of digital stores and every major streaming platform, including Spotify, Apple Music, Amazon Music, Pandora and Google Music.

With Intercept Music, recording artists have all the tools needed to market, promote and sell their music online and through social media. Comprehensive reporting allows artists to track the fan response to their releases, all the way down to individual music tracks.

There are three foundations of Intercept Music’s product offering:

• Its music distribution platform that is well augmented via the company’s partnership with InGrooves, a wholly owned subsidiary of Universal Music, which is arguably one of the largest music companies in the world.
• Its social media system, which is tailored to work the way artists use social media to promote their music and engage with their fans. The scheduling system integrates artists’ profiles across multiple social networking sites (Facebook, Twitter, Instagram and YouTube) to facilitate new audience sampling, fan development and the ability for music to be previewed and purchased.
• The third is represented by the team of developers that brings a unique combination of deep technical expertise (in products like Skype), a team of well-accomplished executives and what the company calls Brand Ambassadors – senior reps from multiple genres who have helped artists earn over 100 Grammys.

Intercept Music is the confluence of technology and this music expertise.

The company currently markets three plans to its clients, with each offering different distribution and royalty options, as well as various marketing and reporting options. The plans are described below:

• Intercept Distro is a basic plan for self-service music distribution with royalty collection. Artists keep 100% of the royalties while receiving unlimited releases and full analytics with reporting.
• Intercept Artist includes all of the benefits of the basic Distro plan with added emphasis on social marketing and distribution for emerging artists. With this plan, artists receive scheduled and ad-hoc posting, social media reporting, reusable content libraries and access to other valuable features.
• Intercept PLUS is available by invite only and is for established artists looking for a complete suite of marketing, distribution and monetization services. The PLUS plan includes everything available through the Distro and Artist plans, as well as offering a dedicated service representative, a branded online store, on-demand merchandise, additional marketing, YouTube monetization and other pro features.

Intercept PLUS is the flagship plan. Artists of this caliber often do $3-$10k/month in merchandise sales alone, at 50%+ profit. Intercept is responsible for marketing to the fan base through its social media system and shares in the profits generated. The stores are managed by intercept so both top-line revenues and bottom-line profits flow through Intercept.

Intercept Music has partnered with Ingrooves Music Group, the largest online music distribution company in the world, for worldwide distribution to streaming services and leading stores. Completing more than 50 billion transactions weekly across over 150 countries, Ingrooves supplies music to leading streaming music platforms and lists some of the world’s largest and most reputable music labels among its clients. The partnership allows Intercept Music and its clients to reach a much wider audience and start earning revenue as soon as possible by leveraging Ingrooves’ quality control systems and direct relationships with leading music streaming services.

Physical Distribution Options for Intercept Music Clients

In a press release on June 25, 2020, Intercept Music announced that it would be offering artists physical distribution through major retailers such as Amazon, FYE and Walmart (https://ibn.fm/G09cu). The physical distribution will consist of CDs and vinyl and will serve as a supplement to the online streaming platform access provided by the company to represented artists.

“In the current climate, artists can’t play shows or otherwise engage in public at all, so they’re focusing on all other opportunities to bring in revenue,” Intercept Music President Tod Turner stated in a news release. “Our only priority is to help artists monetize music in every way, and with physical distribution added to the mix, we’re leaving no stone unturned in helping artists to earn money from their creative output.”

Creation of Preferred Stock

On June 29, 2020, Sanwire CEO Christopher Whitcomb announced that the company would be filing certificates of designation with the Nevada Secretary of State for its Series A, B and C preferred stock (https://ibn.fm/eCcds).

Speaking about this designation in a news release, Whitcomb stated, “Our paramount goal is to maintain a balanced approach between future investments and shareholder value while minimizing shareholder dilution. The effective utilization of preferred stock ensures our company can grow with the least amount of shareholder dilution.”

Sanwire is leveraging a multi-dimensional strategy that includes additional acquisitions, attracting investors and enhancing the current balance sheet while minimizing dilution for shareholders. A primary goal of these efforts is to support Intercept’s ongoing operations.

Financial Highlights

For the fiscal quarter ended June 30, 2020, Sanwire announced significant revenue growth related to the acquisitions of Intercept Music and Art is War Records. Since acquiring Intercept Music in March and Art is War Records in June, Sanwire’s revenue has increased by approximately 300% (https://ibn.fm/BQX82). Sanwire attributes the increase in revenue to Intercept Music’s customer acquisition and the release of its PLUS plan.

For the third quarter, revenue is expected to continue an upward climb, owing largely to physical distribution plans and a rising number of PLUS subscribers. The company’s acquisition of Art is War Records is also expected to fuel this growth.

Management

Christopher M. Whitcomb is the current CEO of Sanwire Corp. and Intercept Music Inc. He is a CPA in the state of California, holding bachelor’s degrees in accounting, corporate finance and business management with a focus on real estate. A seasoned executive, his business ventures are always strongly focused on the development and financing of companies.

Whitcomb worked alongside Ralph Tashjian at SMC Entertainment Inc. and Digital Music Universe. They are currently working together again following Sanwire’s acquisition of Intercept Music, which was founded by Tashjian.

For more information, visit the company’s website at www.SanwireCorporation.com.

NOTE TO INVESTORS: The latest news and updates relating to SNWR are available in the company’s newsroom at https://ibn.fm/SNWR

• POAI’s Soluble Biotech announces first substantial contract with pharmaceutical company since acquisition
• Founder calls contract “major milestone,” validation of move into new facility
• POAI’s Skyline Medical sells eight proprietary STREAMWAY(R) systems to Virginia-based hospital organization

Soluble Biotech, a division of Predictive Oncology (NASDAQ: POAI), has finalized its first substantial contract with a pharmaceutical company since being acquired by POAI earlier this year (https://ibn.fm/gXjd2). Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins and protein complexes. The contract calls for Soluble Biotech’s expertise in protein expression and solubility studies.

“Our first contract is a major milestone and validates our recent move into a new, larger facility,” said Soluble Biotech founder Dr. Larry DeLucas, who is also a former NASA astronaut. “We quadrupled our laboratory and office space, some of which will eventually include a GMP facility. Additionally, we acquired state-of-the-art equipment to support our fermentation, therapeutic protein formulation development and protein stability studies.”

Soluble Biotech is fast becoming recognized for its ability to enhance the drug-development process by rapidly optimizing protein solubility and stability. The company brings proprietary transformational technology to formulation development for protein-based pharmaceutical and vaccines. In addition, its solubilization and stability technology is used at academic, pharmaceutical and government laboratories involved in conducting fundamental protein research.

“With our first contract on the books, and expanded capacity, the future is bright,” said DeLucas. “We are currently negotiating several additional contracts with biotechnology and pharmaceutical companies.”

In addition to this POAI milestone, the company also announced that its Skyline Medical division has sold eight of its proprietary STREAMWAY systems to a large Virginia-based university hospital organization for use in a new surgical center (https://ibn.fm/JQ6AA); the hospital system previously purchased two STREAMWAY systems, which are currently in use.

The FDA-approved and CE-marked STREAMWAY Systems provide automated, direct-to-drain medical fluid disposal that is changing the way health-care facilities collect and dispose of potentially infectious waste fluid. The eight-system sale brings the total systems sold for Q3 2020 up to 13.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• SGTM secures Hurricane Laura recovery work contract for ArborPro of Mississippi Inc.
• Initial relief efforts will divert trees from landfills to temporary holding sites
• SGTM transforms natural storm waste into organic environmentally beneficial products

As “stewards of the environment”, Sustainable Green Team (OTC: SGTM) takes its role in environmental remediation seriously by providing beneficial solutions for tree and storm waste disposal. In the wake of Hurricane Laura, SGTM rose to the occasion by securing a contract for ArborPro of Mississippi Inc. (APM), one of its strategic partners. The recovery work planned will kickstart SGTM’s process, diverting many destroyed trees from landfills to the company’s processing facilities that will transform them into environmentally beneficial organic products.

Considered to be the strongest hurricane to hit Louisiana since 1856, Laura ravaged the state with winds clocking in at over 150 miles per hour as it destroyed vegetation and shredded homes while taking at least 17 lives in the process (https://ibn.fm/LXAc5). Hurricanes of this magnitude inflict massive damage on trees by breaking branches or uprooting them completely, creating a burden for municipalities that often dispose of them in landfills.

SGTM provides synergistic solutions that clear devastated areas of natural waste while creating products that benefit the environment. Through its subsidiary National Storm Recovery, the company collects the trees and transforms them into organic products such as garden mulch and organic playground surfacing material certified by IPEMA, The International Play Equipment Manufacturers Association.

“Our teams are committed to the cleanup process and helping the wonderful people of Louisiana get back on their feet again,” said SGTM CEO and Director Tony Raynor (https://ibn.fm/xsOVe). “Our database of subcontractors is growing daily as the clean-up efforts begin.”

Teams from both SGTM and APM will initially collaborate with subcontractors to remove trees blocking key infrastructure points such as right-of-ways. As part of the initial remediation efforts, the trees will then be transported to temporary debris management sites for storage prior to reaching their final destination at SGTM’s processing facilities.

“I’m proud to be a part of this disaster recovery clean up and with our relationship with National Storm Recovery,” said APM CEO Aaron Miller. “Our combined resources and decades of experience will speed the recovery process.”

SGTM’s solutions are founded in sustainability, based on vertically integrated operations that transform what would be landfill waste into organic, attractive, next-generation playground surface material and mulch products that are packaged and sold to landscapers, installers and garden centers. Through a combination of organic growth, strategic acquisitions and service diversification, the company is positioned for rapid growth as nationwide demand for environmentally sustainable solutions for natural waste continues to increase.

To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/JVHu6.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM

• Pressing need for efficient drug procurement, delivery as costs rise
• Trxade platform speeds up delivery, cuts costs
• Such efficiencies crucial to keeping America’s independent pharmacies alive
• Around half of 24,000 independent pharmacies have already signed on

These days, critics of the U.S. health-care system may be tempering their censure. After all, the sector has proved its worth in the battle against the coronavirus pandemic. Yet some of the fault-finding had merit. The system is bloated and plagued by inefficiencies. Even doctors agree, as a recent report in the “Journal of the American Medical Association” (“JAMA”) indicates (https://ibn.fm/bL7C1). Digital technologies may help streamline processes and methodologies, making some areas, such as pharmaceutical distribution, more efficient and, importantly, more effective. With that in mind, the Trxade Group (NASDAQ: MEDS) has developed a pharmaceutical supply-chain trading platform that is already helping pharmacies cut costs and get faster delivery.

No other country spends more on health care than the United States. National expenditure in the sector accounts for around 18% of gross domestic product (“GDP”). Unfortunately, recent studies have shown a lot of that money just goes down the drain. That conclusion, published in JAMA, details that “approximately 30% of health care spending may be considered waste.”

A major portion of that — $230.7 billion to $240.5 billion — can be attributed to “pricing failure,” which includes “medication pricing, payer-based health services pricing, and laboratory-based and ambulatory pricing.” Of these, medication pricing is posing the biggest challenge, as new high-cost specialty drugs become more widely prescribed. But, say researchers, cost pressures in pharmaceuticals can be reduced by “increasing market competition… and reforming price transparency,” which is exactly what the Trxade pharmaceutical trading platform is designed to do (https://ibn.fm/I0H6D).

The web-based platform allows pharmacies to discover the best-available prices for prescription drugs, a feature that independent pharmacists find especially advantageous. It also helps pharmacies avoid negative reimbursement costs, which reduce already thin profit margins. The Trxade Group is hoping to show most, if not all, of the 24,000 independent pharmacies that its platform is a better deal than the conventional system, and the company appears well on the way to doing so. An estimated 11,400 pharmacies have already signed up.

These cost pressures are particularly trying for independent pharmacies that are competing with giant chains such as CVS, Walgreens, Rite Aid and Walmart. In the past, these smaller businesses have depended on pharmacy benefit managers (“PBMs”) to reduce the purchase costs of drugs. PBMs are third-party administrators of prescription drug programs that were supposed to contribute to lower prices by their consolidation of buying power.

However, it appears the cost savings procured have been mainly used by PBMs to build their own businesses. Some PBMs now have revenues that exceed those of the top pharmaceutical manufacturers. For example, Express Scripts reported revenue of $100 billion in 2017, about twice as much as Pfizer, which is the largest pharmaceutical company in the world. Incredible as it may seem, the distribution of pharmaceuticals is a much more lucrative business than the manufacture of pharmaceuticals. Indeed, distribution margins also exceed those earned by pharmacies at the retail level.

However, the online marketplace hosted by the Trxade Group offers pharmacies a real opportunity to reduce purchase costs. Called the Trxade Exchange, the platform gives small pharmacies access to the wider pharmaceutical distribution network, allowing them to search for and view products from manufacturers, buying groups, and wholesalers on a real-time and continuous basis. By increasing competition and price transparency, the Trxade Exchange is giving today’s independent drugstores a new lease on life.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• KAVL recently announced the Bidi(TM) Vapor Premarket Tobacco Product Application submission to FDA, a premium recyclable vape pen
• Application includes 285,000 pages with science-backed evidence that Bidi(TM) Sticks are Appropriate for Protection of Public Health (“APPH”)
• KAVL and Bidi(TM) Vapor fully support proper regulation of safety manufacturing and marketing of vape products
• Bidi(TM) Sticks are produced in 11 flavors with 6% nicotine concentration

With a focus on growing and incubating innovative products into mature dominant brands, Kaival Brands Innovations Group (OTCQB: KAVL) recently entered into a partnership with Bidi (TM) Vapor, LLC for exclusive global distribution rights for the Bidi(TM) Stick – a new game-changing recyclable vape pen that offers users a premium multi-flavored vaping experience. Bidi(TM) Vapor recently announced that it has submitted its Premarket Tobacco Product Application (“PMTA”) to the U.S. Food and Drug Administration (“FDA”) for approval to continue its marketing efforts in the United States.

Vape pens, also known as electronic cigarettes, are devices used to supplement nicotine with vapor instead of smoke from combustible cigarettes. Accordingly, Bidi(TM) Vapor’s application provides over 285,000 pages of extensive science-based evidence demonstrating how Bidi(TM) Sticks are “Appropriate for the Protection of Public Health” (“APPH”).

“Bidi(TM) Stick is a premium-quality product that adult smokers have discovered can be a viable alternative to combustible tobacco, and we look forward to meeting the increasing market demand for the innovative product,” said Kaival Brands president and CEO Kaival Niraj Patel.

Using science as a foundational base, Bidi(TM) Vapor engineered its electronic nicotine-delivery system (“ENDS”) products using its own patented technology. With stringent quality control standards in place, the company vetted all supplementary raw chemicals and components purchased for the manufacturing process in a cGMP (current Good Manufacturing Practice) facility. Following strict in-vitro and in-vivo toxicity testing (including genotoxicity tests) at a GLP (Good Laboratory Practice)-approved lab, the product was then subjected to an HPHC (Harmful and Potentially Harmful Constituents) analysis of both the aerosol and e-liquid in ISO 17025 certified labs.

Also contained in the PMTA submission were three independent surveys and one combined consumer survey of people aged 21+ conducted by Bidi(TM) Vapor. The application also included specific information concerning the product’s 11 flavors in addition to details on its nicotine concentration that stands at 6% weight/volume.

“Both Kaival Brands and Bidi(TM) Vapor fully support proper regulation of the category so that all ENDS products meet the highest manufacturing, safety and marketing standards for adult smokers, with the ultimate goal of improving public health,” Patel continued. “We look forward to working with Kaival Brands as we work with the FDA to construct its regulatory policy based on science and facts.”

Kaival Brands is dedicated to developing innovative and viable options for adults currently using combustible tobacco products who are opting for a healthier and more satisfying experience. The company intends to set high standards and transform perceptions with the overall goal of exceeding customer expectations and increasing market share in the continuously growing vaping industry.

For more information, visit the company’s website at www.KaivalBrands.com.

NOTE TO INVESTORS: The latest news and updates relating to KAVL are available in the company’s newsroom at http://ibn.fm/KAVL

• GoldHaven to trade on OTCQB under ticker symbol ATUMF
• Move provides liquidity in trading of shares, creates opportunity for American investors to participate in Maricunga Gold Belt activity
• GoldHaven recently entered into agreements to acquire seven gold projects, plans aggressive drill program

GoldHaven Resources (CSE: GOH) (OTCQB: ATUMF), a Canada-based company engaged in the business of acquiring and exploring mineral resource properties, has announced that it has been accepted for trading on the OTCQB (https://ibn.fm/fB9Z3). The OTCQB exchange is a United States stock market based in New York City and operated by OTC Markets Group. The shares will trade on OTCQB under the ticker symbol ATUMF.

“We are very pleased to begin trading on OTCQB and continue our outreach into the U.S,” said GoldHaven president and CEO David Smith. “Further, it will provide liquidity in the trading of its shares and create an opportunity for American investors to participate in the company’s investment in the Maricunga Gold Belt. We look forward to providing the market with frequent updates as we plan on the implementation of an aggressive drill program in the first quarter of the coming year.”

This news comes on the heels of the announcement by GoldHaven that it has recently entered into agreements to acquire seven promising gold projects in the highly productive Maricunga Gold Belt of Chile. Within the past 20 years, discoveries totaling in excess 100 million ounces of gold, 450 million ounces of silver and 1.3 billion pounds of copper have been made in this belt.

Thus far, GoldHaven has identified four of those seven properties as high-priority targets and anticipates beginning a drilling program by January 2021. The process of identifying and categorizing these projects was extensive. Careful field evaluations included mapping, geochemical sampling and satellite imagery.

Location is also a key component for GoldHaven’s Coya project, which is situated within close proximity to one of the richest and largest epithermal gold and silver districts in Chile. The La Coipa property, an active mining site owned and operated by Kinross, is also in close proximity, with reported production of more than 6.2 million ounces of gold to date.

The movement on these projects is particularly timely, given the recent meteoric rise of the price of gold. The current fragile state of the global economy, caused in part by the weakening U.S. dollar, has spurred the price of gold to reach $2,000 an ounce for the first time ever (https://ibn.fm/Zw67Q). Projections call for that number to go even higher, perhaps even reaching $3,000 per ounce (https://ibn.fm/uCdmd). That can only benefit companies such as GoldHaven, which are working to become strong players in the gold space.

GoldHaven is a Canadian junior exploration company active in the Maricunga Gold Belt of Northern Chile. The Maricunga measures 150 km north-south and 30 km. east-west and is host to discoveries in the last 10 years of 100M oz. gold; 450M oz. silver and 13 billion lbs. copper.

For more information, visit the company’s website at www.GoldHavenResources.com.

NOTE TO INVESTORS: The latest news and updates relating to ATUMF are available in the company’s newsroom at http://ibn.fm/ATUMF

• Leading UK scientists, policy group call for rescheduling of psilocybin amid looming mental health crisis
• Sent to the Home Office with statements of support from leading scientists, paper urges for psilocybin use on a research-only model
• Cybin Corp. to capitalize on international expansion of psilocybin use as a company active in both research, nonclinical spaces

The United Kingdom (“UK”) is joining other countries, including Canada, in a push to facilitate the wider use of psilocybin, a naturally occurring compound found in mushrooms. Focusing on psychedelic and nutraceutical products, Cybin Corp. is poised to leverage the growing global momentum the compound is gaining.

Recent clinical studies suggest that psilocybin may be a safe and effective drug for patients with certain treatment-resistant psychiatric illnesses (https://ibn.fm/dsIEN). Despite that, researchers claim their work is hindered by strict controls on the compound. The Adam Smith Institute and the Conservative Drug Policy Reform Group recently published a joint paper that calls for a review of the Schedule 1 status of psilocybin (https://ibn.fm/TMGvg). That status inhibits research efforts despite the compound’s potential to contribute to the treatment of several highly prevalent mental health disorders.

The paper is co-published and authored by leading researchers from prominent academic institutions including King’s College London and the University of Manchester. The authors of the paper propose the re-classification of psilocybin to Schedule 2 of the Misuse of Drugs Regulations 2001 on a research-only basis. Doing so would reduce current barriers to research, enabling the enormously needed exploration of novel mental health treatments by the UK’s scientists.

Psilocybin was used in the psychiatric treatment for resistant forms of depression, anxiety, and addictions before 1970. The drug was banned that year as a result of the U.S.-led war on drugs. Decades later, psilocybin is experiencing a slow but steady revival of research interest. Leading academic institutions are advocating for easier use of the compound in the academic and clinical setting (https://ibn.fm/ud5zY).

Consequently, countries around the world are becoming increasingly accepting of psilocybin use in a controlled setting. Recently, Canada’s health department has allowed its use for palliative care of terminally ill patients (https://ibn.fm/ZkBgz).

Big Pharma has scaled back investment in mental health research, failing to offer more effective treatments for health problems plaguing hundreds of millions of people worldwide (https://ibn.fm/jqSV4). Fortunately, innovative companies are stepping up to fill the growing need for novel psychiatric drugs.

Cybin already holds a unique strength in the psychedelics space. The company is responsible for some of the first published research on microdosing; i.e, the action or practice of taking or administering very small amounts of a drug to test or benefit from its physiological action while minimizing its potentially undesirable side effects. Microdosing sub-hallucinogenic amounts of psychedelic drugs including psilocybin has several potentially positive indications. As such, Cybin is ideally positioned to leverage the growing acceptance of psilocybin in mainstream space.

Cybin is active in two critical sectors: nutraceutical and pharmaceutical. In the nutraceutical market, the company’s wholly owned subsidiary Nature’s Journey focuses on adaptogenic mushroom products. Meanwhile, Cybin is an innovator in the stagnant pharmaceutical market, where it aims to become the first life science company to bring psilocybin medicine targeting major depressive disorder to market (https://ibn.fm/4a2Xw).

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

• CNS Pharmaceuticals is a clinical-stage biotechnology company developing therapies to combat aggressive cancers of the brain and central nervous system
• The company will be applying for approval to launch Phase II trials in the first quarter of 2021 for its leading drug candidate, Berubicin, which targets glioblastoma multiforme (“GBM”) brain cancer
• CNS Pharmaceuticals CEO addressed the company’s achievements and its vision for Berubicin development during the recent 22nd annual Global Investment Conference sponsored by H.C. Wainwright & Co.
• C. Wainwright is a full-service investment bank focused on capital markets and equity research in market sectors that hinge on industries encompassing the healthcare and life sciences, metals and mining, clean tech and technology and telecommunications
• CNS holds a worldwide exclusive license to the Berubicin chemical compound and intends to also launch Phase I trials for its use in pediatric brain tumor patients through its sublicensee partner WPD Pharmaceuticals, as well as to develop a second drug candidate, WP1244, which is a novel agent 500 times more potent than chemotherapy drug daunorubicin in stopping cancer proliferation

CNS Pharmaceuticals (NASDAQ: CNSP) gained an opportunity to expand the reach of its novel brain tumor-targeting drug candidate when CEO John Climaco presented the company’s achievements and vision to potential financial backers at the 22nd annual Global Investment Conference sponsored by H.C. Wainwright & Co. (https://ibn.fm/Lqryu).

CNS Pharmaceuticals has been developing unique treatments for primary and metastatic cancers of the brain and central nervous system, including lead drug candidate, Berubicin, which the company is advancing for federal approval in trials to treat the aggressive brain cancer glioblastoma multiforme (“GBM”), according to a company news release (https://ibn.fm/5mppw).

Climaco’s appearance at the three-day investment conference Sept. 14-16 granted the biopharmaceutical company access to the life sciences investment bank’s trading clients and delivered opportunities for interested parties to visit one-on-one with management team members through the conference’s virtual technology platform. A replay of the Sept. 16 presentation will be available on CNS Pharmaceuticals’ website for 90 days following the event.

CNS Pharmaceuticals has achieved a number of key milestones as part of its preparations for filing an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) later this year to launch Phase II clinical trials for Berubicin.

CNS holds a worldwide exclusive license to the Berubicin chemical compound and has obtained all the data from a Phase I clinical trial completed in 2006 that saw some notable successes. Of 25 patients who could be evaluated, 44 percent experienced a statistically significant improvement in clinical benefit and one person obtained lasting results that has left the patient cancer-free as of the last assessment on Feb. 20, 2020, according to the news release.

When the company begins the anticipated Phase 2 trial in the U.S. in Q1 2021, its sublicensee partner, WPD Pharmaceuticals, also intends to launch in Poland a Phase 2 trial for adult GBM patients along with a Phase 1 trial for pediatric patients with GBM. Meanwhile, CNS continues developing a second drug candidate, WP1244, that is a novel DNA binding agent shown in preclinical studies to be 500 times more potent than the chemotherapeutic agent daunorubicin in stopping tumor cell expansion.

H.C. Wainwright & Co.’s annual Global Investment Conference was an ideal place to attract the financial support necessary to help move the projects forward. The Wainwright company is a full-service, client‐focused organization focused on capital markets and equity research in market sectors that hinge on the healthcare and life science industries, the metals and mining industries, the clean tech industry and technology and telecommunications. The conference’s tracks are divided into those four categories as well as a growth track that tackles scaling, leadership and other aspects of small business success (https://ibn.fm/Rp2o5).

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• SRAX’s BIGtoken’s platform allows companies to gain transparent, instant insights from platform’s 16.7+ million subscribers
• BIGtoken surveyed US user-base in early April and again in August in bid to track changes in US consumer behavior
• Actionable insights gleaned from survey reveal US citizens’ consumption habits

SRAX Inc. (NASDAQ: SRAX), a digital marketing pioneer focused on providing consumer data management services, has recently published the results of a series of surveys carried out by BIGtoken, its proprietary consumer insights platform. BIGtoken enables its platform’s user base of over 16.7 million consumers to both own their data and monetize it in an efficient and transparent manner; in turn, the platform’s customers can submit questionnaires and surveys to BIGtoken’s subscribers, receiving rapid and actionable consumer data in return  to help them better understand and serve their chosen audiences (https://ibn.fm/SZzc8).

In early April, amidst the early throes of the COVID-19 pandemic, BIGtoken surveyed its United States user base to understand how the pandemic had affected their social behaviors. The company subsequently redeployed the same survey in August to compare the results.

The results provided a fascinating insight into the consumption patterns of US-based individuals while also illustrating a remarkable shift in their daily routines over the past few months. The initial feedback regarding social behavior proved to be especially revealing:

• Less people are isolating alone today (29%) than they were four months ago (44%)
• The most popular activities for passing time at home during the pandemic have been streaming movies & TV shows, cooking or baking, playing video games, and using social media
• In April, 43% of respondents said they were exercising more than they were in the prior month. In August however, only 31% said they were exercising more than they were in the previous 4 months
• When asked, in April, “How has social distancing affected the frequency of communication with friends and family?” 42% of respondents said they were communicating more than usual. When asked again in August, only 32% said they were communicating more than usual
• In April, 70% were shopping online, while in August, only 25% were shopping online

Interestingly, while the survey results showed that consumers were less prone to be isolating alone relative to four months prior, consumption of streaming video content has enjoyed an exponential increase (particular in relation to activities such as exercise, which in turn has witnessed a marked decrease in adherents).

• 46% of respondents said in August 2020 that they are video streaming more than they were four months prior.
• More BIGtoken users have subscribed to Netflix, Amazon Prime, and Hulu from April to August 2020.
• Before the coronavirus outbreak, 21% of respondents claimed to have watched one movie per week. Currently, 32% of respondents watch two to three movies per week and 20% watch four to six movies per week.
• Generally, 50% of respondents are watching more TV and movies now than four months ago.

The survey results have matched up to actual trends, with the OTT industry seeking a surge of interest in recent months and the likes of Netflix and Disney+ adding 26 million and 54.5 million paid subscribers over the first half of the year, respectively (https://ibn.fm/4cJwS).

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• SGTM entered packaging agreement with Old Castle Lawn & Garden to supply large Midwest home improvement chains
• Old Castle Lawn & Garden parent company CRH employs 80,300 people at more than 3,100 locations across 30 countries
• SGTM dispatched team to assess damage from Hurricane Laura, one of the strongest in history
• SGTMS’s Q2 results nearly doubled from Q1 to $12.3 million in revenue, $3.4 million in gross profit

As nationwide demand for environmentally sustainable solutions for waste increases, Sustainable Green Team (OTC: SGTM) –a leading provider of environmentally beneficial solutions for tree and storm waste disposal—continues to expand its footprint in the U.S. through a packaging agreement between its subsidiary Mulch Manufacturing Inc. and Old Castle Lawn & Garden to supply large home improvement chains in the Midwest. The recent agreement with Old Castle Lawn & Garden is the latest in a series of strategic moves in line with SGTM’s corporate strategy, which combines operation expansion, strategic acquisitions and internal investment—moves that have enabled the company to expand and profit at a time of global economic contraction.

As a wholly-owned subsidiary of CRH, Old Castle Lawn & Garden provides architectural products that include concrete masonry and hardscapes, packaged cement mixes, packaged lawn and garden products. Its parent company CRH is a leading global diversified building materials group that employs over 80,300 people at more than 3,100 locations across 30 countries (https://ibn.fm/tCAtD).

“I am honored to have been engaged by Old Castle Lawn & Garden and to secure a packaging agreement with this global company, increasing our strategic partnerships,” said SGTM CEO and Director Tony Raynor in recent statements (https://ibn.fm/9olTc).

SGTM provides environmentally-beneficial solutions for tree and storm waste disposal created by hurricanes, ice storms and floods into useful organic products that benefit the environment. Through its subsidiaries, the company provides tree services that include debris hauling, biomass recycling, waste removal, mulch manufacturing, packaging and sales, and most recently the production of playground surface material.

Expert predictions forecasting a very active storm season for Florida are coming to fruition (https://ibn.fm/H0Awm), evidenced by the extent of the damage created by Hurricane Laura, considered to be one of the strongest hurricanes on record as measured by maximum sustained winds (https://ibn.fm/s7tBO). SGTM recently reported that it dispatched its National Storm Recovery Ltd. team to assess the damage and is still on site in impacted areas. Live video coverage of the company’s strategic relief efforts can be viewed online through its social media channels (https://ibn.fm/u24kU).

STGM has been rapidly growing despite a worldwide economic slowdown that has seen millions of businesses closed. The company’s impressive Q2 results almost doubled during the quarter and include over $12.3 million in revenue and $3.4 million in gross profit https://ibn.fm/n825Y. As “stewards of the environment” SGTM plans to continue expanding its operations and diversifying revenue streams amid a growing business landscape that is experiencing increased demand for their organic, sustainable and environmentally-friendly products.

To learn more about Sustainable Green Team Ltd., view the investor presentation at https://ibn.fm/177U7.

NOTE TO INVESTORS: The latest news and updates relating to SGTM are available in the company’s newsroom at http://ibn.fm/SGTM